ITEM VIEW

Toxoplasma gondii seroprevalence studies on humans and animals in Africa

dc.contributor.authorHammond-Aryee, Kenneth Nii Ofeien_ZA
dc.contributor.authorEsser, Monikaen_ZA
dc.contributor.authorVan Helden, Paul D.en_ZA
dc.date.accessioned2016-06-27T14:12:49Z
dc.date.available2016-06-27T14:12:49Z
dc.date.issued2014
dc.identifier.citationHammond-Aryee, K. N. O., Esser, M. & Van Helden, P. D. 2014. Toxoplasma gondii seroprevalence studies on humans and animals in Africa. South African Family Practice, 56(2): 119-124
dc.identifier.issn2078-6204 (online)
dc.identifier.issn2078-6190 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/99055
dc.descriptionCITATION: Hammond-Aryee, K. N. O., Esser, M. & Van Helden, P. D. 2014. Toxoplasma gondii seroprevalence studies on humans and animals in Africa. South African Family Practice, 56(2): 119-124.
dc.descriptionThe original publication is available at http://www.safpj.co.za
dc.description.abstractBackground: Toxoplasmosis is a disease caused by Toxoplasma gondii, which can infect nearly all mammalian and avian species. Approximately 25% of the global human population is thought to be infected. Interest in toxoplasmosis has surged since it was discovered that with the onset of acquired immune deficiency syndrome, acute toxoplasmosis could induce cranial calcification. The ensuing encephalitis can be fatal. The African human immunodeficiency virus (HIV) epidemic, increasing levels of other immunosuppressive infections (such as tuberculosis), poor sanitation practices and lack of monitoring of at-risk populations point to a predicament that may be underrated. Objective: The objective was to review the available body of research on the seroepidemiology of T. gondii in Africa, in order to establish existing prevalence trends and to draw attention to available information on the pathogen in Africa. Method: The National Center for Biotechnology Information, Google Scholar and ToxoDB databases were searched for peer-reviewed articles that focus specifically on seroprevalence studies of T. gondii in Africa up until the 2012 year end. Results: Seroprevalence rates on the continent are high in humans and animals. There is a geographical trend of decreasing seroprevalence from the northern to the southern, and from the western to the eastern, regions of the continent. Most seroprevalence studies on humans were reported between 1981 and 2000. Conclusion: There is a need for further and more consolidated information on the prevalence of T. gondii in Africa, in order to address morbidity and mortality from opportunistic but treatable diseases, such as toxoplasmosis in the ongoing HIV pandemic, and to improve the lives of the African population.en_ZA
dc.description.urihttp://www.safpj.co.za/index.php/safpj/article/view/3843
dc.format.extent6 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherMedpharm Publicationsen_ZA
dc.subjectToxoplasmosisen_ZA
dc.subjectToxoplasma gondiien_ZA
dc.subjectToxoplasmosis in animalsen_ZA
dc.titleToxoplasma gondii seroprevalence studies on humans and animals in Africaen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderSouth African Academy of Family Physiciansen_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW